NXC 401 - Nexcella
Alternative Names: NXC-401 - NexcellaLatest Information Update: 13 Jan 2023
At a glance
- Originator Nexcella
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 20 Dec 2022 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) (Nexcella pipeline December 2022)